The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Michael W. Weiner; Dallas P. Veitch; Paul S. Aisen; Laurel A Beckett; Nigel J. Cairns; Robert C. Green; Danielle J Harvey; Clifford R. Jack; William Jagust; John C. Morris; Ronald C. Petersen; Jennifer Salazar; Andrew J. Saykin; Leslie M. Shaw; Arthur W. Toga; John Q. Trojanowski

doi:10.1016/j.jalz.2016.10.006

The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Michael W. Weiner, Dallas P. Veitch, Paul S. Aisen, Laurel A Beckett, Nigel J. Cairns, Robert C. Green, Danielle J Harvey, Clifford R. Jack, William Jagust, John C. Morris, Ronald C. Petersen, Jennifer Salazar, Andrew J. Saykin, Leslie M. Shaw, Arthur W. Toga, John Q. Trojanowski

Public Health Sciences

Research output: Contribution to journal › Article

46 Scopus citations

Abstract

Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. Methods: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Results: Multimodal analyses will provide insight into AD pathophysiology and disease progression. Discussion: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.

Original language	English (US)
Journal	Alzheimer's and Dementia
DOIs	https://doi.org/10.1016/j.jalz.2016.10.006
State	Accepted/In press - 2016

Keywords

Alzheimer's disease
Amyloid phenotyping
Brain Health Registry
Centiloid method
Clinical trial biomarkers
Functional connectivity
Tau imaging

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Geriatrics and Gerontology
Clinical Neurology
Cellular and Molecular Neuroscience
Psychiatry and Mental health

Access to Document

10.1016/j.jalz.2016.10.006

Fingerprint Dive into the research topics of 'The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement'. Together they form a unique fingerprint.

Cite this

Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W., Morris, J. C., Petersen, R. C., Salazar, J., Saykin, A. J., Shaw, L. M., Toga, A. W., & Trojanowski, J. Q. (Accepted/In press). The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia. https://doi.org/10.1016/j.jalz.2016.10.006

The Alzheimer's Disease Neuroimaging Initiative 3 : Continued innovation for clinical trial improvement. / Weiner, Michael W.; Veitch, Dallas P.; Aisen, Paul S.; Beckett, Laurel A; Cairns, Nigel J.; Green, Robert C.; Harvey, Danielle J; Jack, Clifford R.; Jagust, William; Morris, John C.; Petersen, Ronald C.; Salazar, Jennifer; Saykin, Andrew J.; Shaw, Leslie M.; Toga, Arthur W.; Trojanowski, John Q.

In: Alzheimer's and Dementia, 2016.

Research output: Contribution to journal › Article

Weiner, MW, Veitch, DP, Aisen, PS, Beckett, LA, Cairns, NJ, Green, RC, Harvey, DJ, Jack, CR, Jagust, W, Morris, JC, Petersen, RC, Salazar, J, Saykin, AJ, Shaw, LM, Toga, AW & Trojanowski, JQ 2016, 'The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement', Alzheimer's and Dementia. https://doi.org/10.1016/j.jalz.2016.10.006

Weiner, Michael W. ; Veitch, Dallas P. ; Aisen, Paul S. ; Beckett, Laurel A ; Cairns, Nigel J. ; Green, Robert C. ; Harvey, Danielle J ; Jack, Clifford R. ; Jagust, William ; Morris, John C. ; Petersen, Ronald C. ; Salazar, Jennifer ; Saykin, Andrew J. ; Shaw, Leslie M. ; Toga, Arthur W. ; Trojanowski, John Q. / The Alzheimer's Disease Neuroimaging Initiative 3 : Continued innovation for clinical trial improvement. In: Alzheimer's and Dementia. 2016.

@article{dc5ce421427d49198660a850cc9129ba,

title = "The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement",

abstract = "Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. Methods: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Results: Multimodal analyses will provide insight into AD pathophysiology and disease progression. Discussion: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.",

keywords = "Alzheimer's disease, Amyloid phenotyping, Brain Health Registry, Centiloid method, Clinical trial biomarkers, Functional connectivity, Tau imaging",

author = "Weiner, {Michael W.} and Veitch, {Dallas P.} and Aisen, {Paul S.} and Beckett, {Laurel A} and Cairns, {Nigel J.} and Green, {Robert C.} and Harvey, {Danielle J} and Jack, {Clifford R.} and William Jagust and Morris, {John C.} and Petersen, {Ronald C.} and Jennifer Salazar and Saykin, {Andrew J.} and Shaw, {Leslie M.} and Toga, {Arthur W.} and Trojanowski, {John Q.}",

year = "2016",

doi = "10.1016/j.jalz.2016.10.006",

language = "English (US)",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The Alzheimer's Disease Neuroimaging Initiative 3

T2 - Continued innovation for clinical trial improvement

AU - Weiner, Michael W.

AU - Veitch, Dallas P.

AU - Aisen, Paul S.

AU - Beckett, Laurel A

AU - Cairns, Nigel J.

AU - Green, Robert C.

AU - Harvey, Danielle J

AU - Jack, Clifford R.

AU - Jagust, William

AU - Morris, John C.

AU - Petersen, Ronald C.

AU - Salazar, Jennifer

AU - Saykin, Andrew J.

AU - Shaw, Leslie M.

AU - Toga, Arthur W.

AU - Trojanowski, John Q.

PY - 2016

Y1 - 2016

N2 - Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. Methods: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Results: Multimodal analyses will provide insight into AD pathophysiology and disease progression. Discussion: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.

AB - Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. Methods: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Results: Multimodal analyses will provide insight into AD pathophysiology and disease progression. Discussion: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.

KW - Alzheimer's disease

KW - Amyloid phenotyping

KW - Brain Health Registry

KW - Centiloid method

KW - Clinical trial biomarkers

KW - Functional connectivity

KW - Tau imaging

UR - http://www.scopus.com/inward/record.url?scp=85008701998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008701998&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.10.006

DO - 10.1016/j.jalz.2016.10.006

M3 - Article

C2 - 27931796

AN - SCOPUS:85008701998

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

ER -